Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP | MicrobiomeTrials← Back to trialsNCT07354074
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-04-28Est. Completion: 2033-02-23
Enrollment target: 50 participants Locations- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- Columbia University Medical Center New York Presbyterian, New York, New York, United States
- Cinn Children Hosp Medical Center, Cincinnati, Ohio, United States
- Seattle Childrens Hospital, Seattle, Washington, United States
- Novartis Investigative Site, Brisbane, Queensland, Australia
- Novartis Investigative Site, North Adelaide, South Australia, Australia
- Novartis Investigative Site, Rio de Janeiro, Rio de Janeiro, Brazil
- Novartis Investigative Site, Barretos, São Paulo, Brazil
- Novartis Investigative Site, São Paulo, São Paulo, Brazil
- Novartis Investigative Site, Edmonton, Alberta, Canada
- Novartis Investigative Site, Montreal, Quebec, Canada
- Novartis Investigative Site, Zhengzhou, Henan, China
- Novartis Investigative Site, Tianjin, China
- Novartis Investigative Site, Marseille, France
- Novartis Investigative Site, Paris, France
- Novartis Investigative Site, Poitiers, France
Other microbiome trials you might be interested in
B Acute Lymphoblastic Leukemia
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemothe…
Birmingham, United StatesEst. completion Dec 1, 2030
Chronic Myeloid Leukemia
The aim of this study is to evaluate the real-world effectiveness and safety of asciminib among young adults with chroni…
Multiple LocationsEst. completion Jul 30, 2027
Novartis Investigative Site, Strasbourg, FranceNovartis Investigative Site, Frankfurt am Main, Hesse, GermanyNovartis Investigative Site, Erlangen, GermanyNovartis Investigative Site, Debrecen, Hajdu Bihar Megye, HungaryNovartis Investigative Site, Padova, PD, ItalyNovartis Investigative Site, Roma, RM, ItalyNovartis Investigative Site, Yokohama, Kanagawa, JapanNovartis Investigative Site, Fukuoka, JapanNovartis Investigative Site, Saitama, JapanNovartis Investigative Site, Utrecht, NetherlandsNovartis Investigative Site, Gdansk, PolandNovartis Investigative Site, Wroclaw, PolandNovartis Investigative Site, Seoul, South KoreaNovartis Investigative Site, Seoul, South KoreaNovartis Investigative Site, Barcelona, SpainNovartis Investigative Site, Madrid, SpainNovartis Investigative Site, Madrid, SpainNovartis Investigative Site, Bangkok, ThailandPhase 1
Recruiting
Malignancy, HematologicNeoplasms, HematologicNeoplasms, HematopoieticBlood CancerHematological NeoplasmsHematopoietic MalignanciesDysmyelopoietic SyndromesHematopoetic MyelodysplasiaMyeloid Leukemia, AcuteNonlymphoblastic Leukemia, AcuteLeukemia, Lymphocytic, Acute
Background:
Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RA…
Bethesda, United StatesEst. completion Apr 30, 2029